Drug lookup | Fillwise

ETHOSUXIMIDE

All products: general benefit

Other products in the same Health Canada class (N03A) — coverage varies; not interchangeable

Carbamazepine (Tegretol): general benefit, Limited Use, Not a benefit, Listing status unconfirmed
Clonazepam (Rivotril): general benefit
Divalproex (Epival): general benefit
Lamotrigine (Lamictal): general benefit
Phenytoin diphenylhydantoin (Dilantin-30 Suspension): general benefit
Phenytoin diphenylhydantoin (Dilantin): general benefit, Limited Use 481, 657

14 more in the class list below

Zarontin · DIN 00023485 · 50mg/mL · oral liquid

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Zarontin · DIN 00023485 Manufacturer: Searchlight Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-10-11 · brand ZARONTIN SYRUP · ATC N03AD01 ETHOSUXIMIDE · form Syrup · route Oral · ingredients ETHOSUXIMIDE 250 MG/5ML · company Searchlight pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Zarontin: Formulary list price $0.0740/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0740 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=731 · Verify on the e-Formulary ↗ (DIN 00023485)

Source record

DIN 00023485: Zarontin Raw flags: sec3=Y Item: 281200009; group id 429; item number 1069; lccId None; manufacturer id SLP Source form: O/L; strength: 50mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0740; ministry $0.0740 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00023485 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=731

Shortage status: resolved shortage (ended 2022-05-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00023485

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more

Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS ZARONTIN / ZARONTIN SYRUP (ethosuximide) is indicated for the control of absence (petit mal) epilepsy. 1.1 Pediatrics Pediatrics (3-17 years): Safety and effectiveness in pediatric patients below the age of 3 years have not been established (see 4.2 Recommended Dose and Dosage Adjustment). 1.2 Geriatrics No data are available to Health Canada. Caution should be exercised in dose selection for an elderly patient, recognizing the more frequent hepatic and renal dysfunctions. https://pdf.hres.ca/dpd_pm/00068265.PDF PM date: OCT 11, 2022 Source product: ZARONTIN; DIN 00022799; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.